Medpace (MEDP) told investors cancellations were “well behaved” and a 1.15 book-to-bill was still in reach. Growth looked steady. Backlog looked strong. Confidence stayed high. But the complaint alleges that this optimism masked worsening cancellation trends that undermined that guidance.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
A federal securities lawsuit filed against Medpace Holdings Inc. claims the company misled investors about a critical bookings metric while allegedly concealing the true state of cancellation trends and backlog cancellations, resulting in a sharp stock decline when the truth allegedly emerged.
Investors who purchased Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, may have suffered losses connected to allegations that the company made materially false and misleading statements about its anticipated book-to-bill ratio for the fourth quarter of 2025. On February 10, 2026, Medpace shares fell more than 15.9%, dropping from $530.35 to $446.05 per share, after the company disclosed a fourth-quarter book-to-bill ratio of 1.04, well below the 1.15 level the complaint alleges Medpace repeatedly signaled for the second half of 2025 and into the fourth quarter.
If you purchased Medpace Holdings stock during the class period and want to learn more about your potential rights, you may wish to consult with a securities attorney.
What Medpace Does and Why Its Backlog Metrics Matter
Medpace Holdings Inc. is a clinical contract research organization (CRO) that provides outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company’s operating model centers on full-service Phase I through Phase IV clinical development and therapeutic expertise. Medpace is headquartered in Cincinnati, Ohio, and its common stock traded on the NASDAQ under the ticker symbol MEDP during the relevant period.
For a company like Medpace, the book-to-bill ratio is a closely watched metric that measures the value of new business awarded relative to revenue recognized. A ratio above 1.0 indicates that the company is winning more business than it is burning through, which signals future revenue growth. Because this metric depends heavily on new contract awards and the rate at which existing contracts are canceled, management commentary on cancellation trends carries significant weight with investors and analysts.
What Plaintiffs Allege Medpace Got Wrong
The lawsuit, filed in the United States District Court for the Southern District of Ohio, alleges that Medpace and its top executives repeatedly misled investors about the company’s anticipated book-to-bill ratio for the fourth quarter of 2025, while allegedly concealing the true state of cancellation trends and backlog cancellations. Plaintiff Jan Durbin, individually and on behalf of all others similarly situated, alleges that Defendants portrayed an overly optimistic picture of business conditions throughout the class period, telling investors a 1.15 book-to-bill ratio was achievable in the second half of 2025 even as cancellations were allegedly deteriorating.
The complaint further alleges that management described cancellations as well-behaved and suggested they did not reflect a weak underlying business environment, leading investors to believe conditions were stabilizing when the complaint alleges they were not. The result, the plaintiff claims, was that investors purchased Medpace stock at artificially inflated prices during the class period.
If you are following this case and want updates as it develops, consider monitoring public filings for more information.
How Medpace Management Described Business Conditions During the Class Period
Throughout the class period, Medpace management made a series of statements on quarterly earnings calls that the lawsuit claims were false and misleading. On April 22, 2025, during the earnings call covering first-quarter results, CEO August James Troendle acknowledged that a downside scenario might produce a book-to-bill ratio around 1.0, but stated that the company still had paths to reaching 1.15. He described this as the kind of downside scenario he saw, suggesting confidence that the higher target remained achievable.
On July 22, 2025, during the earnings call, Troendle stated that the company saw strong potential for book-to-bill to return to above 1.15x in the third quarter and described cancellations in that period as very well-behaved. On the October 23, 2025, call covering third-quarter results, Troendle again characterized cancellations as well-behaved, noting they permitted record net bookings and a book-to-bill of 1.20 that quarter. CFO Kevin M. Brady also described third-quarter performance as broad-based and not isolated to a handful of studies, which the complaint contrasts with the later disclosure that fourth-quarter cancellations were skewed toward the metabolic area.
When the Alleged Truth Came Out
The alleged corrective disclosure occurred after the market closed on February 9, 2026, when Medpace published its fourth quarter 2025 earnings results. The company reported net new business awards of $736.6 million and a book-to-bill ratio of just 1.04x for the fourth quarter, well below the 1.15 level management had repeatedly indicated or suggested was achievable.
On February 10, 2026, during the earnings call, Troendle acknowledged that cancellations were elevated again in the fourth quarter, and that backlog cancellations in absolute and percent terms were the highest they had been in over a year. Troendle stated he did not anticipate the fourth-quarter spike, though the complaint alleges the defendants had access to non-public information about the company’s backlog that should have informed their prior guidance. Following that disclosure, Medpace shares fell from $530.35 to $446.05, a decline of more than 15.9% in a single trading session.
Why This Lawsuit Could Matter to Medpace Shareholders
The lawsuit centers on whether Medpace and its executives gave investors an accurate picture of cancellation trends and backlog health while consistently pointing to a 1.15 book-to-bill target as reasonable and achievable. If the allegations are proven, investors who bought Medpace stock during the class period at prices allegedly inflated by those statements may have suffered real economic losses when the stock declined sharply following the February 2026 disclosure.
The complaint also highlights that management’s assurance that revenue was broad-based and not concentrated in a handful of studies, contrasted with its later admission that fourth quarter cancellations were skewed toward the metabolic therapeutic area, which had been a growing segment. This alleged mismatch between prior reassurances and subsequent disclosures is central to the plaintiff’s theory of investor harm.
Legal Claims at the Center of the Case
The complaint asserts two counts under the federal securities laws. Count I is brought against all defendants under Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, which prohibit fraudulent or misleading statements made in connection with the purchase or sale of securities. Count II is brought against the individual defendants, CEO August James Troendle, President Jesse J. Geiger, and CFO Kevin M. Brady, under Section 20(a) of the Exchange Act, which imposes liability on individuals who exercise control over a company that commits securities fraud.
The plaintiff alleges that defendants knowingly or recklessly made false and misleading statements about the company’s book-to-bill guidance and cancellation rates while concealing material adverse information from the investing public.
If you purchased Medpace Holdings stock during the class period and would like to learn more about your legal rights as a shareholder, you may wish to consult a qualified securities attorney.
About Levi & Korsinsky, LLP
Levi & Korsinsky, LLP is a nationally recognized securities litigation firm representing investors in complex shareholder actions. The firm has extensive expertise and a team of over 70 employees to serve our clients. Attorney advertising. Prior results do not guarantee similar outcomes.
Disclaimer: This article is provided for informational purposes only and does not constitute legal advice. No attorney-client relationship is created by reading this article. Past results do not guarantee similar outcomes.